ABBV Insider Trading

Insider Ownership Percentage: 0.25%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $73,278,511.54

AbbVie Insider Trading History Chart

This chart shows the insider buying and selling history at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$11MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal Insider BuyingTotal Insider Selling

AbbVie Share Price & Price History

Current Price: $201.16
Price Change: Price Decrease of -0.176 (-0.09%)
As of 03/26/2025 04:59 PM ET

This chart shows the closing price history over time for ABBV up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$201.16Closing price on 03/26/25:

SEC Filings (Institutional Ownership Changes) for AbbVie (NYSE:ABBV)

70.23% of AbbVie stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ABBV by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$18Bbought$12BsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10B$0$10BTotal InflowsTotal Outflows
AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More on AbbVie

Today's Range

Now: $201.16
Low: $196.49
High: $203.12

50 Day Range

MA: $195.65
Low: $169.19
High: $216.62

52 Week Range

Now: $201.16
Low: $153.58
High: $218.66

Volume

6,742,701 shs

Average Volume

5,275,588 shs

Market Capitalization

$355.13 billion

P/E Ratio

83.82

Dividend Yield

3.09%

Beta

0.61

Who are the company insiders with the largest holdings of AbbVie?

AbbVie's top insider investors include:
  1. Richard A Gonzalez (CEO)
  2. Richard A Gonzalez (Chairman)
  3. Azita Saleki-Gerhardt (EVP)
  4. Robert A Michael (COO)
  5. Jeffrey Ryan Stewart (EVP)
  6. Nicholas Donoghoe (EVP)
  7. Timothy J Richmond (EVP)
  8. Elaine K Sorg (SVP)
  9. Perry C Siatis (EVP)
  10. Scott T Reents (CFO)
  11. Kevin K Buckbee (SVP)
Learn More about top insider investors at AbbVie.

Who are the major institutional investors of AbbVie?

AbbVie's top institutional shareholders include:
  1. Vanguard Group Inc. — 9.79%
  2. Geode Capital Management LLC — 2.10%
  3. Capital Research Global Investors — 1.92%
  4. Capital International Investors — 1.61%
  5. Charles Schwab Investment Management Inc. — 1.55%
  6. Norges Bank — 1.42%
Learn More about top institutional investors of AbbVie stock.

Which major investors are selling AbbVie stock?

In the previous quarter, ABBV stock was sold by these institutional investors:
  1. Capital International Investors
  2. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main
  3. Janus Henderson Group PLC
  4. International Assets Investment Management LLC
  5. T. Rowe Price Investment Management Inc.
  6. Legal & General Group Plc
  7. Bank of New York Mellon Corp
  8. Ontario Teachers Pension Plan Board
Within the previous year, company insiders that have sold AbbVie company stock include:
  1. Richard A Gonzalez (CEO)
  2. Richard A Gonzalez (Chairman)
  3. Azita Saleki-Gerhardt (EVP)
  4. Robert A Michael (COO)
Learn More investors selling AbbVie stock.

Which major investors are buying AbbVie stock?

In the previous quarter, ABBV stock was acquired by institutional investors including:
  1. Norges Bank
  2. Raymond James Financial Inc.
  3. FMR LLC
  4. Charles Schwab Investment Management Inc.
  5. Franklin Resources Inc.
  6. Northern Trust Corp
  7. Deutsche Bank AG
  8. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC